Medovex Corp. To Present Its New DeNerveX Product - Small Cap Street

NEW YORK, Oct. 1, 2015 /PRNewswire/ -- Medovex Corp. (NASDAQ: MDVX) shares closed yesterday at $2.38 up 1.28%. Trading volume was slightly softer than the daily average at 18,780 shares. MDVX shares started out the year at $5.32 and have gradually declined in price. The low was $2.12 per share on August 25th and the price has gotten some traction since then.

Our due diligence will show investors of Medovex the necessary information they should be aware of. Get our report at no cost by using the link below. Readers will also find information on the recent success that members of Small Cap Street have had.

http://bit.ly/-MDVX_Due_Diligence

Copy and paste to browser may be required.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options.

About Small Cap Street

We make the connection between sophisticated investors and high quality public companies. An issuer of reports written by financial analysts who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.

Safe Harbor Statement

This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors, which may affect forward-looking statements. The company assumes no duty to update its forward-looking statements.

Compliance Procedure  

Content is researched, written and reviewed on a best-effort basis by a 3^rd party research provider. However, we are only human and may make mistakes. This report was prepared for informational purposes only.  A full disclaimer can be found by viewing the full analyst report. We do not hold any positions and have not been compensated in any form for this press release and coinciding reports. For more information and services provided beyond this press release please use contact information provided below. If you notice any errors or omissions, please notify us.

Source: Small Cap Street             

Contact: editor@smallcapstreet.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/medovex-corp-to-present-its-new-denervex-product--small-cap-street-300152377.html

SOURCE Small Cap Street